La catena delle opzioni mostra i dati chiave delle opzioni azionarie di  a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ..

 (OTC:BITW) Azioni, Catena delle Opzioni

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

Bitwise Crypto Industry Innovators ETF

Bitwise Ethereum ETF Common shares of beneficial interest

Bitwise Funds Trust Bitwise Bitcoin Strategy Optimum Roll ETF

Bitwise Funds Trust Bitwise Bitcoin and Ether Equal Weight Strategy ETF

Bitwise Funds Trust Bitwise Ethereum Strategy ETF

Bitwise Funds Trust Bitwise Web3 ETF

News

Asset Sales

KODK

Kodak Retirement Income Plan Trust Sells $764.4M In Illiquid Assets To Mastercard Foundation For $550.6M Cash, Signs Additional Agreements For $87.3M Sale To Other Investors, Retaining $161.3M In Illiquid Assets And $917.2M In Hedge Fund Assets Pending Redemption Proceeds

<p>D. Boral Capital  analyst Jason Kolbert   maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.</p>


Price Target

Analyst Ratings

AVXL

D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

<p>Loop Capital  analyst Alan Gould   maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Hold and lowers the price target from $38 to $35.</p>


Loop Capital Maintains Hold on Warner Music Gr, Lowers Price Target to $35

<p>Dear Damon shareholders, supporters, reservation holders and enthusiasts,</p>
<p>I am deeply grateful for your steadfast support and dedication over the past two and half years – a period that has proven challenging for us all. Your belief in our mission has been a cornerstone of our perseverance during a time when many early-stage startups struggled to survive. You deserve a transparent account of the journey we have endured together and an understanding of the hurdles that has led us to where we are now, starting with a roadmap of what we need to do to get to production.</p>
<p><strong>Path To Production, Explained</strong></p>
<p>Currently with 15 in-house engineers, we are leveraging a combination of our employees alongside key subcontractors and external experts to advance development. Late-stage engineering is mostly complete, with vehicle mechanics 90% finalized. Power electronics are also 90% complete, with ongoing validation and the integration of key features. Similarly, mechanical and cooling systems are 90% complete, while the battery system is 70% complete, with efforts focused on the development of the cell interconnect system.</p>
<p>With adequate funding, the project is expected to progress to the pre-production stage,&nbsp;starting with validation and design confirmation, where we'll aim to make a run of pre-production prototypes and test them against our design requirements and regulations to confirm the designs before we release to tooling. Ordering all the tools to make our first run of parts from will be the next big milestone, subject to our ability to raise sufficient capital to make this substantial investment. This pre-production phase has an estimated completion of late 2025. The Production &amp; Commercialization Stage is expected to occur in parallel, focusing on the establishment of the final assembly and test facility at our HQ in San Rafael, CA, along with the development of distribution and delivery infrastructure. This stage is expected to conclude in 2026 and pending additional capital to achieve, serial production can then begin.</p>
<p>Commercial production is expected to commence after passing various internal and external tests and undergoing a self-certification process required for US-bound vehicle homologation. These tests include: the completion of Damon's ride quality and long-term durability testing, completion of FCC Title 47 certification for the onboard charger, completion of UN 38.3 battery testing, completion of Damon's internal battery testing, extreme temperature operation verification, brake testing per FMVSS, and an internal and external review of FMVSS compliance with our engineering subcontractor.</p>
<p><strong>What Led Us Here</strong></p>
<p>In the spring of 2022, Damon successfully raised a US$26M Series B financing, which marked the beginning of our efforts to raise a Series C round with the assistance of two major banks. This funding was intended to kickstart production. However, following the volatile SPAC era, the financial landscape shifted dramatically. The bursting of this bubble led to a severe downturn in the markets, and our efforts to secure a Series C production financing were unsuccessful. Despite these circumstances, the company was able to bridge itself with the support of various investors - enough to cover essential costs, having significantly reduced expenses across the board.</p>
<p><strong>Navigating Funding Challenges</strong></p>
<p>Since early 2022, inflation rates grew to reach 40-year highs, the highest level since 1981. Simultaneously. interest rates reached 20-year highs, rocking the financial markets and virtually wiping out risk capital for private companies, especially for pre-revenue startups in the capital-intensive automotive sector. Because of this, pre-revenue electric vehicle company valuations fell by an average 85%, and <i>very few</i> survived. Damon is an anomaly that persevered, despite how little risk capital had been available to fund the company's path to production. As previously noted, the company had undertaken multiple cost-cutting measures across all areas to navigate through these challenging past two years. These necessary reductions have regrettably led to significant delays. The journey has been far from easy, but these tough decisions were essential to ensure our continued operation and future success.</p>
<p>Nevertheless, we&nbsp;<i>have</i> persevered - a testament to everyone's faith and resilience when compared to many high-tech automotive startups that did not survive. And now that we are on the Nasdaq, the dream of reinventing motorcycling is far from over.</p>
<p><strong>Going Public&nbsp;</strong></p>
<p>After all this, it became evident that transitioning to the public markets was the best viable route to secure the necessary funding for production. In October 2023, we signed a merger agreement with Grafiti Holdings. Why did we choose Grafiti? &nbsp;It was the best merger partner we identified, possessing the ability to provide us with bridge financing and additional funding sources to help fund our Nasdaq preparation efforts and the benefit of no debt or liabilities.</p>
<p>During the 13-months it took to complete the merger and secure our Nasdaq listing, we faced what oftentimes seemed like insurmountable challenges. These included maintaining essential operations, keeping the remaining staff onboard, and managing increasing costs associated with going public. Additionally, we had to navigate the arduous, tax, audit and public listing requirements of both Canada and the US. These demands impacted our ability to fund production preparations, which are costly, thus extending our timeline to production.</p>
<p>Fast forward to now, and we achieved the goal of getting listed on the Nasdaq. Now, as a public company, we hope to gain access to the additional capital we need to fund our path to production. And this is why we need your continuing faith, your support and your confidence in us. Because we still have a lot of work ahead of us.</p>


Damon CEO Pens Letter Providing Business Update And Outlining Production Roadmap

<p>On Friday, the FDA approved <strong>BridgeBio Pharma, Inc.&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42150289/attruby-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce-cardiovascular-deat" rel="noreferrer noopener">cardiovascular-related hospitalization</a>.</p>
<p>The FDA approval is based on ATTRibute-CM Phase 3 study results, which showed that Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42072773/bridgebio-pharmas-acoramidis-shows-competitive-edge-against-pfizers-tafamidisa-in-lucrative-but-competitive-attr-cm-market" rel="noreferrer noopener">BridgeBio Pharma&#8217;s Acoramidis Shows Competitive Edge Against Pfizer&#8217;s Tafamidisa In Lucrative But Competitive ATTR-CM Market</a></strong></p>
<p>Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR.</p>
<p>Attruby was designed to mimic a naturally occurring &#8220;rescue mutation&#8221; of the TTR gene (T119M) that targets the root cause of ATTR-CM, the destabilization of the native TTR tetramer.</p>
<p>Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes.</p>
<p>The ATTRibute-CM Phase 3 study enrolled 632 participants with symptomatic ATTR-CM associated with either wild-type or variant TTR.</p>
<p>BridgeBio submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025.</p>
<p>BridgeBio has granted&nbsp;<strong>Bayer AG</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>)&nbsp;exclusive rights to commercialize acoramidis for ATTR-CM in Europe.</p>
<p>The company said it will provide Attruby for free to patients who participated in the trial.</p>
<p><strong>William Blair</strong> writes, &#8220;We continue to view a reduction in all-cause mortality on label as a necessary distinction to gain major market share in ATTR-CM alongside <strong>Pfizer Inc&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) tafamidis.&#8221;</p>
<p>Since the Attruby label doesn&#8217;t include data on overall mortality, the William Blair analyst notes Pfizer might shift its marketing focus to emphasize claims about mortality benefits.</p>
<p><strong>Price Action:</strong> BBIO stock is up 24.3% at $29.10 during the premarket session at last check Monday.</p>
<p><em>Image via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/contracts/24/11/42162996/vertical-aerospace-soars-50-million-funding-boost-and-debt-conversion-propel-evtol-maker-forward" target="_blank" rel="noreferrer noopener">Vertical Aerospace Soars: $50 Million Funding Boost And Debt Conversion Propel eVTOL Maker Forward</a></strong></li>
</ul>


Analyst Color

Biotech

Equities

Health Care

Movers

Trading Ideas

General

BAYRY

BBIO

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

<p><i>The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET</i></p>
<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.januxrx.com%2F&amp;esheet=54157214&amp;newsitemid=20241125381273&amp;lan=en-US&amp;anchor=Janux+Therapeutics%2C+Inc.&amp;index=1&amp;md5=e257bbb56600d7291454ec697d3b55f8">Janux Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event on Monday, December 2, 2024, at 4:30 PM ET.</p>
<p>David Campbell, Ph.D., President &amp; Chief Executive Officer, will provide an update on JANX007 Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).</p>


JANX

Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In mCRPC And Doses Selected For Phase 1b Expansion Studies

<p>The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.</p>
<p>Here's the latest list of major oversold players in this sector, having an RSI near or below 30.</p>
<h3 class="wp-block-heading"><strong>Office Properties Income Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>)</strong></h3>
<ul>
<li>On Oct. 30, Office Properties IT reported worse-than-expected third-quarter FFO results. The company's stock fell around 40% over the past month and has a <a href="https://www.benzinga.com/quote/OPI">52-week low of $1.06</a>.</li>
<li><strong>RSI Value:</strong> 20.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>OPI Price Action:</strong> Shares of Office Properties Income Trust closed at $1.14 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">latest OPI news</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261.png" alt="" class="wp-image-662916" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261-768x701.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</strong></h3>
<ul>
<li>On Nov. 15, Wheeler Real Estate Investment Trust announced a 1-for-2 reverse stock split effective Nov. 18. The company's stock fell around 32% over the past five days and <a href="https://www.benzinga.com/quote/WHLR">has a 52-week low</a> of $5.79.</li>
<li><strong>RSI Value:</strong> 26.03</li>
<li><strong>WHLR Price Action:</strong> Shares of Wheeler Real Estate Investment Trust fell 2.2% to close at $8.50 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">trend in WHLR stock</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262.png" alt="" class="wp-image-662917" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Creative Media &amp; Community Trust Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>)</strong></h3>
<ul>
<li>On Nov. 8, Creative Media reported a quarterly loss of $1.22 per share which missed the analyst consensus estimate of a loss of 64 cents per share. &#8220;We continue to make progress on our previously announced actions to accelerate our focus towards premier multifamily assets, strengthen our balance sheet and improve our liquidity,&#8221; said David Thompson, Chief Executive Officer of Creative Media &amp; Community Trust Corporation. The company's stock fell around 25% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/CMCT">low of $0.21.</a></li>
<li><strong>RSI Value:</strong> 21.55</li>
<li><strong>CMCT Price Action:</strong> Shares of Creative Media &amp; Community Trust fell 9.1% to close at $0.22 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">breakout in CMCT shares</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263.png" alt="" class="wp-image-662923" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></strong></li>
</ul>


Long Ideas

Pre-Market Outlook

Markets

CMCT

WHLR

Top 3 Real Estate Stocks That May Explode In Q4

<p><br /><i>icometrix' FDA-cleared quantitative brain solution for neurological conditions including Alzheimer's and multiple sclerosis is seamlessly integrated into Philips next generation BlueSeal MR scanners, and will be deployed in its comprehensive informatics platform</i><br />&nbsp;</p>


Events

Philips And Icometrix Report Results Of MRI Brain Scans To Optimize Alzheimer And Multiple Sclerosis Diagnosis At RSNA 2024

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Outperform and maintains $42 price target.</p>


BBWI

Telsey Advisory Group Maintains Outperform on Bath & Body Works, Maintains $42 Price Target

<p><i>Partnership enhances gift card shopping experience with quick local deliveries from DashMart and other popular merchants within the DoorDash app</i></p>
<p>ATLANTA, Nov. 25, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310547-1&amp;h=4183263924&amp;u=https%3A%2F%2Fwww.incomm.com%2F&amp;a=InComm+Payments">InComm Payments</a>, a global payments technology company, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310547-1&amp;h=4056120216&amp;u=https%3A%2F%2Fwww.doordash.com%2F&amp;a=DoorDash">DoorDash</a>, the premier local commerce platform, today announced a partnership enabling consumers to browse, purchase and order delivery of gift cards for hundreds of merchants within the DoorDash app. The offering will launch on Friday, Nov. 29, with promotions beginning on Black Friday that offer&nbsp;limited-time discounts on select digital gift card orders made through the app or website&#x2A; by eligible customers.</p>


DASH

DoorDash Selects InComm Payments As Partner To Launch In-App Gift Card Shopping Experience

<p>Loop Capital  analyst Jeffrey Stevenson   maintains GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) with a Hold and raises the price target from $85 to $93.</p>


Loop Capital Maintains Hold on GMS, Raises Price Target to $93

<p>Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Nutanix to report an <strong>earnings per share</strong> (EPS) of $0.30.</p>
<p>The announcement from Nutanix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.07, leading to a 20.31% increase in the share price on the subsequent day.</p>
<p>Here's a look at Nutanix's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.20</td>
<td>0.16</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.28</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>20.0%</td>
<td>-23.0%</td>
<td>7.000000000000001%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543326_0.png" alt="eps graph" /></p>
<h3>Performance of Nutanix Shares</h3>
<p>Shares of Nutanix were trading at $73.18 as of November 22. Over the last 52-week period, shares are up 80.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NTNX/earnings"><strong>To track all earnings releases for Nutanix visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

NTNX

What to Expect from Nutanix's Earnings

<p>Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) will release its quarterly earnings report on Tuesday, 2024-11-26. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Nordstrom to report an <strong>earnings per share</strong> (EPS) of $0.22.</p>
<p>Nordstrom bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.25 in the last quarter, leading to a 4.21% increase in the share price on the following day.</p>
<p>Here's a look at Nordstrom's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.71</td>
<td>-0.07</td>
<td>0.88</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>-0.24</td>
<td>0.96</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>5.0%</td>
<td>-16.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543318_0.png" alt="eps graph" /></p>
<h3>Market Performance of Nordstrom's Stock</h3>
<p>Shares of Nordstrom were trading at $23.24 as of November 22. Over the last 52-week period, shares are up 51.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Nordstrom</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Nordstrom.</p>
<p>The consensus rating for Nordstrom is Neutral, derived from 9 analyst ratings. An average one-year price target of $22.44 implies a potential 3.44% downside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Ollie's Bargain Outlet, Kohl's and Savers Value Village, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Ollie's Bargain Outlet is favoring an Outperform trajectory, with an average 1-year price target of $106.12, suggesting a potential 356.63% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Kohl's, with an average 1-year price target of $21.0, implying a potential 9.64% downside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Savers Value Village, with an average 1-year price target of $10.0, indicating a potential 56.97% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Ollie's Bargain Outlet, Kohl's and Savers Value Village, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nordstrom</td>
<td>Neutral</td>
<td>3.23%</td>
<td>$1.49B</td>
<td>13.68%</td>
</tr>
<tr>
<td>Ollie's Bargain Outlet</td>
<td>Outperform</td>
<td>12.41%</td>
<td>$219.03M</td>
<td>3.14%</td>
</tr>
<tr>
<td>Kohl's</td>
<td>Neutral</td>
<td>-4.18%</td>
<td>$1.60B</td>
<td>1.73%</td>
</tr>
<tr>
<td>Savers Value Village</td>
<td>Neutral</td>
<td>0.53%</td>
<td>$224.02M</td>
<td>5.09%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Nordstrom ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. Nordstrom is at the top for gross profit. For return on equity, Nordstrom is in the middle compared to its peers.</p>
<h3>Discovering Nordstrom: A Closer Look</h3>
<p>Nordstrom is a fashion retailer that operates about 93 department stores and more than 260 off-price Nordstrom Rack stores. The company also operates both full- and off-price e-commerce sites, two clearance stores, and seven Local locations. Nordstrom's largest merchandise categories are women's apparel (27% of 2023 sales), shoes (26% of 2023 sales), men's apparel (15% of 2023 sales), and beauty (13% of 2023 sales). Nordstrom, which traces its history to a shoe store opened in Seattle in 1901, continues to be partially owned and managed by members of the eponymous family.</p>
<h3>Nordstrom's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Nordstrom's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.23%</strong> as of 31 July, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Nordstrom's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>3.13%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Nordstrom's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>13.68%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.43%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>4.46</strong>, Nordstrom faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/JWN/earnings"><strong>To track all earnings releases for Nordstrom visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: Nordstrom's Quarterly Earnings

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.elastic.co%2F&amp;esheet=54157245&amp;newsitemid=20241125938547&amp;lan=en-US&amp;anchor=Elastic&amp;index=1&amp;md5=e528425de165a4f8983fc7a63ab6b7b4">Elastic</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>), the Search AI Company, announced today it is strengthening its relationship with Amazon Web Services (AWS) by leveraging the latest generative artificial intelligence (AI) services from AWS. As part of this collaboration, Elastic is offering large language model (LLM) observability support for Amazon Bedrock in Elastic Observability. Amazon Bedrock is a fully managed service that offers a choice of high-performing foundation models (FMs) from leading AI companies via a single API, along with a broad set of capabilities organizations need to build generative AI applications with security, privacy, and responsible AI.</p>
<p>The new integration offers Site Reliability Engineers (SREs) detailed insights into their Amazon Bedrock LLMs performance and usage. SREs can now leverage Elastic Observability to monitor invocations, errors, and latency metrics. This allows them to more proactively prevent incidents and identify root causes, ensuring optimal performance for their Amazon Bedrock-powered generative AI applications. Additionally, Elastic AI Assistant, which utilizes Amazon Bedrock, helps SREs accurately analyze data, generate visualizations, and provides actionable recommendations for issue resolution.</p>


ESTC

Elastic Now Collaborates With AWS To Leverage Generative AI Capabilities; Elastic Is Offering Large Language Model Observability Support For Amazon Bedrock In Elastic Observability

<p>Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-26. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Kohl's will report an <strong>earnings per share</strong> (EPS) of $0.31.</p>
<p>Investors in Kohl's are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.14, leading to a 0.61% increase in the share price on the subsequent day.</p>
<p>Here's a look at Kohl's's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.45</td>
<td>0.04</td>
<td>1.28</td>
<td>0.33</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.59</td>
<td>-0.24</td>
<td>1.67</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>7.000000000000001%</td>
<td>-0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543310_0.png" alt="eps graph" /></p>
<h3>Kohl's Share Price Analysis</h3>
<p>Shares of Kohl's were trading at $17.03 as of November 22. Over the last 52-week period, shares are down 27.62%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Views on Kohl's</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Kohl's.</p>
<p>Analysts have provided Kohl's with 6 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $21.0, suggesting a potential 23.31% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of  and Savers Value Village, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Savers Value Village received a Neutral consensus from analysts, with an average 1-year price target of $10.0, implying a potential 41.28% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for  and Savers Value Village, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kohl's</td>
<td>Neutral</td>
<td>-4.18%</td>
<td>$1.60B</td>
<td>1.73%</td>
</tr>
<tr>
<td>Savers Value Village</td>
<td>Neutral</td>
<td>0.53%</td>
<td>$224.02M</td>
<td>5.09%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Kohl's ranks higher than its peers in terms of revenue growth, with a negative growth rate compared to a positive growth rate for its peers. However, it lags behind in gross profit, with a lower figure compared to its peers. In return on equity, Kohl's also falls short, with a lower percentage compared to its peers. Overall, Kohl's is positioned in the middle among its peers based on these metrics.</p>
<h3>All You Need to Know About Kohl's</h3>
<p>Kohl's operates about 1,176 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 26% of its 2023 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.</p>
<h3>Kohl's: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Kohl's's financials over 3 months reveals challenges. As of 31 July, 2024, the company experienced a decline of approximately <strong>-4.18%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>1.77%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.73%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Kohl's's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.46%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.95</strong>, Kohl's adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/KSS/earnings"><strong>To track all earnings releases for Kohl's visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Kohl's's Upcoming Earnings

<p>JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) will release its quarterly earnings report on Tuesday, 2024-11-26. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate JM Smucker to report an <strong>earnings per share</strong> (EPS) of $2.49.</p>
<p>Anticipation surrounds JM Smucker's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.27, which was followed by a 0.82% drop in the share price the next day.</p>
<p>Here's a look at JM Smucker's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.17</td>
<td>2.33</td>
<td>2.27</td>
<td>2.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.44</td>
<td>2.66</td>
<td>2.48</td>
<td>2.59</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543301_0.png" alt="eps graph" /></p>
<h3>Performance of JM Smucker Shares</h3>
<p>Shares of JM Smucker were trading at $113.3 as of November 21. Over the last 52-week period, shares are up 3.39%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on JM Smucker</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding JM Smucker.</p>
<p>The consensus rating for JM Smucker is Neutral, based on 7 analyst ratings. With an average one-year price target of $126.71, there's a potential 11.84% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Pilgrims Pride, Lamb Weston Hldgs and Conagra Brands, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Pilgrims Pride received a Neutral consensus from analysts, with an average 1-year price target of $47.0, implying a potential 58.52% downside.</li>
<li>Lamb Weston Hldgs received a Neutral consensus from analysts, with an average 1-year price target of $74.36, implying a potential 34.37% downside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Conagra Brands, with an average 1-year price target of $31.75, indicating a potential 71.98% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Pilgrims Pride, Lamb Weston Hldgs and Conagra Brands, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>JM Smucker</td>
<td>Neutral</td>
<td>17.72%</td>
<td>$797.20M</td>
<td>2.39%</td>
</tr>
<tr>
<td>Pilgrims Pride</td>
<td>Neutral</td>
<td>5.16%</td>
<td>$683.97M</td>
<td>8.82%</td>
</tr>
<tr>
<td>Lamb Weston Hldgs</td>
<td>Neutral</td>
<td>-0.67%</td>
<td>$356M</td>
<td>7.03%</td>
</tr>
<tr>
<td>Conagra Brands</td>
<td>Neutral</td>
<td>-3.76%</td>
<td>$739.30M</td>
<td>5.45%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>JM Smucker ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, JM Smucker is at the bottom.</p>
<h3>Get to Know JM Smucker Better</h3>
<p>J.M. Smucker is a packaged food company that primarily sells through the US retail channel (78% of fiscal 2024 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of Hostess and international (primarily Canada). Retail coffee is its largest category (33% of sales) with brands Folgers and Dunkin'. Pet foods (22% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from consumer foods, primarily peanut butter and jelly, through brands Jif and Smucker's. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.</p>
<h3>JM Smucker: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, JM Smucker showcased positive performance, achieving a revenue growth rate of <strong>17.72%</strong> as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> JM Smucker's net margin excels beyond industry benchmarks, reaching <strong>8.71%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> JM Smucker's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.39%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> JM Smucker's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.91%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> JM Smucker's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.11</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/SJM/earnings"><strong>To track all earnings releases for JM Smucker visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


An Overview of JM Smucker's Earnings

<p><strong>Arrowhead Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-26. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Arrowhead Pharma will report an <strong>earnings per share</strong> (EPS) of $-1.05. </p>
<p>The market awaits Arrowhead Pharma's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.83 in the last quarter, leading to a 9.44% drop in the share price on the following day.</p>
<p>Here's a look at Arrowhead Pharma's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.55</td>
<td>-0.16</td>
<td>-0.82</td>
<td>-0.60</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.38</td>
<td>-1.02</td>
<td>-1.24</td>
<td>-1.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-9.0%</td>
<td>-11.0%</td>
<td>-5.0%</td>
<td>-27.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543293_0.png" alt="eps graph" /></p>
<h3>Arrowhead Pharma Share Price Analysis</h3>
<p>Shares of Arrowhead Pharma were trading at $18.54 as of November 22. Over the last 52-week period, shares are down 35.89%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ARWR/earnings"><strong>To track all earnings releases for Arrowhead Pharma visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ARWR

A Look Ahead: Arrowhead Pharma's Earnings Forecast

Management

California Resources Appoints Clio Crespy As CFO

<p>Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 5 years by 22.29% on an annualized basis producing an average annual return of 35.93%. Currently, Murphy USA has a market capitalization of $11.04 billion. </p>
<p><strong>Buying $100 In MUSA:</strong> If an investor had bought $100 of MUSA stock 5 years ago, it would be worth <strong>$464.00</strong> today based on a price of $545.34 for MUSA at the time of writing.</p>
<h3>Murphy USA's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543285_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MUSA

$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today

<p>CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-26. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that CrowdStrike Holdings will report an <strong>earnings per share</strong> (EPS) of $0.81.</p>
<p>The announcement from CrowdStrike Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.07, leading to a 2.83% increase in the share price the following trading session.</p>
<p>Here's a look at CrowdStrike Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.97</td>
<td>0.89</td>
<td>0.82</td>
<td>0.74</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>0.93</td>
<td>0.95</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>12.0%</td>
<td>11.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732543284_0.png" alt="eps graph" /></p>
<h3>Market Performance of CrowdStrike Holdings's Stock</h3>
<p>Shares of CrowdStrike Holdings were trading at $372.26 as of November 22. Over the last 52-week period, shares are up 75.3%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analyst Observations about CrowdStrike Holdings</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on CrowdStrike Holdings.</p>
<p>CrowdStrike Holdings has received a total of 39 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $337.64, the consensus suggests a potential 9.3% downside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Fortinet, Palo Alto Networks and Zscaler, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Fortinet, with an average 1-year price target of $93.16, suggesting a potential 74.97% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Palo Alto Networks, with an average 1-year price target of $421.68, indicating a potential 13.28% upside.</li>
<li>As per analysts' assessments, Zscaler is favoring an Outperform trajectory, with an average 1-year price target of $215.46, suggesting a potential 42.12% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Fortinet, Palo Alto Networks and Zscaler, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrowdStrike Holdings</td>
<td>Outperform</td>
<td>31.74%</td>
<td>$726.47M</td>
<td>1.75%</td>
</tr>
<tr>
<td>Fortinet</td>
<td>Neutral</td>
<td>13.00%</td>
<td>$1.24B</td>
<td>90.26%</td>
</tr>
<tr>
<td>Palo Alto Networks</td>
<td>Outperform</td>
<td>13.88%</td>
<td>$1.58B</td>
<td>6.33%</td>
</tr>
<tr>
<td>Zscaler</td>
<td>Outperform</td>
<td>30.30%</td>
<td>$462.66M</td>
<td>-1.26%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>CrowdStrike Holdings ranks at the top for Revenue Growth and Gross Profit among its peers. It is at the bottom for Return on Equity. Overall, CrowdStrike Holdings is positioned favorably compared to its peers based on the provided metrics.</p>
<h3>About CrowdStrike Holdings</h3>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<h3>Unraveling the Financial Story of CrowdStrike Holdings</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining CrowdStrike Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>31.74%</strong> as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> CrowdStrike Holdings's net margin excels beyond industry benchmarks, reaching <strong>4.88%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> CrowdStrike Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.75%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> CrowdStrike Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.67%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.28</strong>.</p>
<p><a href="https://www.benzinga.com/quote/CRWD/earnings"><strong>To track all earnings releases for CrowdStrike Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CRWD

Earnings Outlook For CrowdStrike Holdings

Crypto bill can be passed this year, Schumer says, as Democrats woo industry

BITW: The 'Trump Trade' At A Discount

Crypto rally broadens to Cardano, Solana, Shiba Inu and Dogecoin

BITW: High Beta Crypto Play In An ETF Format

SA Sentiment: More subscribers open to investing in crypto

U.S. Private Sector Prints $299 Billion Surplus And This Points To Higher Equity Prices In November

Bitcoin tops the $97,000 level: A closer look at financial conditions

SA Sentiment: Should the U.S. create a Strategic Bitcoin Reserve?

This is the level Bitcoin would have to reach under Trump to match Biden and his prior term

This is the level Bitcoin would have to reach under Trump to match Biden and his own prior term

AFMC

AFSM

ARKA

ARKB

ARKC

ARKK

ARKW

ARKY

AVUV

BAPR

BETE

BETH

BITB

BITC

BITF

BITI

BITO

BITQ

BITS

BITU

BITW

BITX

BKCH

BKKT

BLKC

BLOK

BRRR

BTCO

BTCW

BTOP

CLSK

COIN

CRPT

DAPP

DEFI

EETH

ETHA

ETHE

EZBC

FBTC

FDIG

FETH

GBTC

HIVE

HODL

HOOD

IBIT

IBLC

IVOO

IVOV

MAGS

MARA

MSTR

RIOT

SATO

SBIT

SPBC

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSPY

STCE

SVAL

SYLD

TMDV

TPHD

TPLC

TPSC

UAUG

UJAN

UMAR

UOCT

UPRO

USMC

USMF

USVM

WGMI

Press Releases

Bitwise Debuts National TV Ad on Bitcoin — "Bitwise Is Interesting"

NYSE Arca Files Form 19b-4 To Uplist the Bitwise 10 Crypto Index Fund (BITW) as an ETP

Comments

(BITW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO